NetWorth
LeaderPortfolio
family
R
Rank #2290
CHINA•Healthcare•Pharmaceutical

Ren Jinsheng & family

Net Worth
$1.792B
+1.2% (24h)
Ren Jinsheng, the founder and chairman of Simcere Pharmaceutical Group, is a prominent figure in the healthcare industry, with an estimated net worth of $2.1 billion as of March 2024. His wealth stems from the pharmaceutical sector, where he has built a successful career. Ren's career includes founding Simcere in 1995, transforming it into an R&D-driven company focused on innovative drugs for various therapeutic areas. He holds degrees from Nanjing University of Chinese Medicine and Nanjing Normal University. His leadership has been instrumental in the company's growth, including its listing on the NYSE in 2007 and subsequent listing on the Hong Kong Stock Exchange.

How to read Ren Jinsheng & family's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Ren Jinsheng & family, we anchor the narrative to Pharmaceutical and Pharmaceutical, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $1.792B alongside global rank #2290, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (CHINA) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Education

Ren Jinsheng was born in 1963. He graduated from Nanjing University of Chinese Medicine in 1982 with a diploma in Chinese Materia Medica. He later obtained a Master's degree in Business Administration from Nanjing Normal University in 1996. After graduating, he worked at Qidong Pharmaceutical Factory before venturing into entrepreneurship.

Rise to Success

Ren Jinsheng's entrepreneurial journey began in March 1995 when he founded Simcere Pharmaceutical Group. Starting with limited capital, Simcere initially focused on distribution. Ren Jinsheng has been the Chairman and CEO since 2004. Under his leadership, Simcere transitioned into a pharmaceutical manufacturing company. Simcere was listed on the NYSE in 2007 and later listed on the Hong Kong Stock Exchange in 2020. In 2025, the Ren Jinsheng family was ranked #382 on the Hurun Rich List, with a fortune of 17 billion yuan, which skyrocketed by 127% compared to the previous year. In December 2025, Simcere Zaiming signed an exclusive licensing agreement with Ipsen Pharma SAS for a potential $1.06 billion.

Key Business Strategies

Ren Jinsheng strategically transformed Simcere from a generics-focused company to an innovation and R&D-driven pharmaceutical company. The company focuses on neuroscience, oncology, autoimmune, and anti-infection therapies. This strategic shift included building an in-house R&D team. He also emphasized attracting top research talent to realize Simcere's ambitions.

Philanthropy

While specific philanthropy amounts are not readily available, Ren Jinsheng's leadership reflects a commitment to improving healthcare. The company's mission, “for patients, for life,” highlights a focus on patient well-being.

Career Timeline

2020

Listing on Hong Kong Stock Exchange

Successfully listed SIMCERE PHARMA on the Hong Kong Stock Exchange

2007

NYSE Listing

Became the first bio and chemical pharmaceutical company in China to be listed on the NYSE.

1995

Founded Simcere Pharmaceutical Group

Founded Jiangsu Simcere, engaging in the sales, marketing and distribution of pharmaceuticals.

1982

Graduation

Graduated from Nanjing University of Chinese Medicine.

Philanthropic Impact

Healthcare$XB

Healthcare Initiatives

Supports healthcare advancements through Simcere Pharmaceutical Group.

Key Business Ventures & Holdings

CompanyStakeValue
Simcere Pharmaceutical Group Ltd4.79%$1.47M

Net Worth History

In-Depth Analysis

Early Life and Education

Ren Jinsheng was born in 1963. He graduated from Nanjing University of Chinese Medicine in 1982 with a diploma in Chinese Materia Medica. He later obtained a Master's degree in Business Administration from Nanjing Normal University in 1996. After graduating, he worked at Qidong Pharmaceutical Factory before venturing into entrepreneurship.

Rise to Success

Ren Jinsheng's entrepreneurial journey began in March 1995 when he founded Simcere Pharmaceutical Group. Starting with limited capital, Simcere initially focused on distribution. Ren Jinsheng has been the Chairman and CEO since 2004. Under his leadership, Simcere transitioned into a pharmaceutical manufacturing company. Simcere was listed on the NYSE in 2007 and later listed on the Hong Kong Stock Exchange in 2020. In 2025, the Ren Jinsheng family was ranked #382 on the Hurun Rich List, with a fortune of 17 billion yuan, which skyrocketed by 127% compared to the previous year. In December 2025, Simcere Zaiming signed an exclusive licensing agreement with Ipsen Pharma SAS for a potential $1.06 billion.

Key Business Strategies

Ren Jinsheng strategically transformed Simcere from a generics-focused company to an innovation and R&D-driven pharmaceutical company. The company focuses on neuroscience, oncology, autoimmune, and anti-infection therapies. This strategic shift included building an in-house R&D team. He also emphasized attracting top research talent to realize Simcere's ambitions.

Philanthropy

While specific philanthropy amounts are not readily available, Ren Jinsheng's leadership reflects a commitment to improving healthcare. The company's mission, “for patients, for life,” highlights a focus on patient well-being.

Data Sources & Methodology

Figures for Ren Jinsheng & family are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom